Eli Lilly and Company (LLY)

Last Closing Price: 365.25 (2022-11-25)

Company Description

Eli Lilly and Company, one of the world's largest pharmaceutical companies, boasts a diversified product profile including a solid lineup of new successful drugs. It also has a dependable pipeline as it navigates through challenges like patent expirations of several drugs and rising pricing pressure on its U.S. diabetes franchise. Its pharmaceutical product categories are neuroscience, diabetes, oncology, immunology and others. Over the past few years, Lilly has been actively seeking acquisitions and in-licensing deals to boost its product portfolio and pipeline. The purchase of ImClone Systems brought with it cancer compound, Erbitux. The acquisition of ICOS Corporation gave Lilly full control over erectile dysfunction drug, Cialis. Its other acquisitions include Hypnion, Inc., CoLucid Pharmaceuticals added Reyvow for acute migraine, Loxo Oncology and Dermira. Lilly has collaboration agreements with several companies including Incyte, Boehringer Ingelheim and Innovent Biologics among others.

Financials, Fundamental Metrics & Ratios
Revenue (Most Recent Fiscal Year) $28.32B
Net Income (Most Recent Fiscal Year) $5.58B
PE Ratio (Current Year Earnings Estimate) 47.01
PE Ratio (Trailing 12 Months) 43.79
PEG Ratio (Long Term Growth Estimate) 2.30
Price to Sales Ratio (Trailing 12 Months) 11.87
Price to Book Ratio (Most Recent Quarterly Book Value per Share) 34.14
Price to Cash Ratio (Most Recent Annual Cash Flow per Share) 38.89
Pre-Tax Margin (Trailing 12 Months) 22.40%
Net Margin (Trailing 12 Months) 20.63%
Return on Equity (Trailing 12 Months) 80.80%
Return on Assets (Trailing 12 Months) 15.90%
Current Ratio (Most Recent Fiscal Quarter) 1.13
Quick Ratio (Most Recent Fiscal Quarter) 0.88
Debt to Common Equity (Most Recent Fiscal Quarter) 1.39
Inventory Turnover (Trailing 12 Months) 1.84
Book Value per Share (Most Recent Fiscal Quarter) $9.57
Earnings per Share (Most Recent Fiscal Quarter) $1.98
Earnings per Share (Most Recent Fiscal Year) $8.16
Diluted Earnings per Share (Trailing 12 Months) $6.66
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers - General
Common Shares Outstanding 950.18M
Free Float 949.04M
Market Capitalization $347.05B
Average Volume (Last 20 Days) 3.19M
Beta (Past 60 Months) 0.36
Percentage Held By Insiders (Latest Annual Proxy Report) 0.12%
Percentage Held By Institutions (Latest 13F Reports) 82.45%
Annual Dividend (Based on Last Quarter) $3.92
Dividend Yield (Based on Last Quarter) 1.07%